Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

NCT03118843 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: SOF/VEL/VOX

Sponsor

Gilead Sciences